113 related articles for article (PubMed ID: 9929111)
1. Heterogeneity of clonal development in chronic myeloproliferative disorders.
Ferraris AM; Mangerini R; Racchi O; Rapezzi D; Rolfo M; Casciaro S; Gaetani GF
Am J Hematol; 1999 Feb; 60(2):158-60. PubMed ID: 9929111
[TBL] [Abstract][Full Text] [Related]
2. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.
Mitterbauer G; Winkler K; Gisslinger H; Geissler K; Lechner K; Mannhalter C
Am J Clin Pathol; 1999 Jul; 112(1):93-100. PubMed ID: 10396290
[TBL] [Abstract][Full Text] [Related]
3. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Spivak JL
Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
[TBL] [Abstract][Full Text] [Related]
4. Clonal analysis of granulocyte-monocyte colony-forming unit cells with the human androgen receptor gene in chronic myeloid leukemia.
Akel S; Mavroyanni D; Yataganas X; Terpos E; Meletis J; Anargyrou K; Stavrogianni N; Pangalis GA; Loukopoulos D; Viniou N
Int J Hematol; 2003 Jun; 77(5):476-81. PubMed ID: 12841386
[TBL] [Abstract][Full Text] [Related]
5. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia.
O'Malley DP; Orazi A; Wang M; Cheng L
Mod Pathol; 2005 Dec; 18(12):1562-8. PubMed ID: 16118625
[TBL] [Abstract][Full Text] [Related]
6. Clonality analysis using X-chromosome inactivation patterns by HUMARA-PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan.
Shih LY; Lin TL; Dunn P; Wu JH; Tseng CP; Lai CL; Wang PN; Kuo MC
Exp Hematol; 2001 Feb; 29(2):202-8. PubMed ID: 11166459
[TBL] [Abstract][Full Text] [Related]
7. Evidence of clonality in chronic neutrophilic leukaemia.
Böhm J; Kock S; Schaefer HE; Fisch P
J Clin Pathol; 2003 Apr; 56(4):292-5. PubMed ID: 12663642
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
9. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Nakata Y
Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
[TBL] [Abstract][Full Text] [Related]
10. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement.
Tsukamoto N; Morita K; Maehara T; Okamoto K; Sakai H; Karasawa M; Naruse T; Omine M
Br J Haematol; 1994 Feb; 86(2):253-8. PubMed ID: 7911034
[TBL] [Abstract][Full Text] [Related]
11. Clonality in juvenile chronic myelogenous leukemia.
Busque L; Gilliland DG; Prchal JT; Sieff CA; Weinstein HJ; Sokol JM; Belickova M; Wayne AS; Zuckerman KS; Sokol L
Blood; 1995 Jan; 85(1):21-30. PubMed ID: 7803795
[TBL] [Abstract][Full Text] [Related]
12. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes.
Champion KM; Gilbert JG; Asimakopoulos FA; Hinshelwood S; Green AR
Br J Haematol; 1997 Jun; 97(4):920-6. PubMed ID: 9217198
[TBL] [Abstract][Full Text] [Related]
13. Ph-positive and -negative myeloproliferative syndromes may co-exist.
Mauro MJ; Loriaux M; Deininger MW
Leukemia; 2004 Jul; 18(7):1305-7. PubMed ID: 15103389
[No Abstract] [Full Text] [Related]
14. Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients.
Sashida G; Ohyashiki JH; Ito Y; Ohyashiki K
Leuk Res; 2002 Sep; 26(9):825-30. PubMed ID: 12127558
[TBL] [Abstract][Full Text] [Related]
15. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission.
Delforge M; Demuynck H; Verhoef G; Vandenberghe P; Zachée P; Maertens J; Van Duppen V; Boogaerts MA
Br J Haematol; 1998 Jul; 102(2):486-94. PubMed ID: 9695963
[TBL] [Abstract][Full Text] [Related]
16. Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders.
Pajor L; Lacza A; Kereskai L; Jáksó P; Egyed M; Iványi JL; Radványi G; Dombi P; Pál K; Losonczy H
Mod Pathol; 2004 Dec; 17(12):1521-30. PubMed ID: 15257312
[TBL] [Abstract][Full Text] [Related]
17. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Pingali SR; Mathiason MA; Lovrich SD; Go RS
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
[TBL] [Abstract][Full Text] [Related]
18. Clonality markers in polycythaemia and primary thrombocythaemia.
Briere J; el-Kassar N
Baillieres Clin Haematol; 1998 Dec; 11(4):787-801. PubMed ID: 10640217
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
20. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
